Semaglutide 10 mg

Περιγραφή

Semaglutide is a long-acting GLP-1 receptor agonist engineered to mimic the activity of endogenous glucagon-like peptide-1 while providing substantially longer biological activity than the native hormone. Unlike Τιρζεπατίδη και Ρετατρουτίδη, Semaglutide activates only the GLP-1 receptor, making it the simplest member of the current generation of incretin peptides. This selective mechanism has made Semaglutide one of the most extensively investigated metabolic peptides in both preclinical and clinical research over the past decade.

Because of this large body of evidence, Semaglutide is frequently used as the reference compound when evaluating newer dual- and triple-receptor agonists.

Why Semaglutide remains important in metabolic research

Although newer multi-receptor agonists have attracted considerable attention, Semaglutide continues to serve as the scientific benchmark for GLP-1 biology.

Published research has investigated Semaglutide in relation to:

• appetite regulation
• body-weight reduction
• glycaemic control
• insulin secretion
• gastric emptying
• cardiovascular outcomes
• metabolic syndrome
• non-alcoholic fatty liver disease
• long-term incretin signalling

Its extensive clinical literature makes Semaglutide one of the most important comparator molecules in obesity and metabolic research. Many modern studies evaluating Tirzepatide, Retatrutide and emerging GLP-1 combinations use Semaglutide as the reference standard.

How Semaglutide works

Semaglutide selectively activates the GLP-1 receptor, a key regulator of appetite, glucose homeostasis and gastrointestinal signalling.

Activation of GLP-1 receptors has been associated in published research with:

• glucose-dependent insulin secretion
• suppression of glucagon release
• delayed gastric emptying
• reduced food intake
• altered central appetite signalling
• improvements in several metabolic markers

Unlike Tirzepatide, Semaglutide does όχι activate GIP receptors. Unlike Retatrutide, it has no glucagon receptor activity.

Its value therefore lies in providing a well-characterised single-pathway GLP-1 model, making it the logical comparator for newer incretin compounds.

Published clinical findings on Semaglutide

Semaglutide has one of the largest human evidence bases of any peptide currently used in metabolic research.

In the STEP clinical programme, once-weekly Semaglutide produced substantial reductions in body weight over 68-week treatment periods, establishing GLP-1 receptor agonism as a major therapeutic strategy for obesity research.

Beyond weight-related outcomes, multiple large clinical programmes have demonstrated improvements in:

• HbA1c
• fasting glucose
• waist circumference
• blood pressure
• selected cardiovascular outcomes
• cardiometabolic risk markers

Because these findings have been reproduced across numerous independent trials, Semaglutide remains the principal benchmark against which newer dual- and triple-agonist peptides are evaluated.

Δημοσιευμένα δεδομένα ασφάλειας και ανεκτικότητας

Published clinical studies consistently identify gastrointestinal events as the most common adverse effects associated with Semaglutide. Frequently reported events include: nausea, vomiting, diarrhoea, constipation and abdominal discomfort.

Across the major clinical programmes, these events were generally most pronounced during dose escalation and were typically described as ήπια έως μέτρια in severity. As with other GLP-1 receptor agonists, gradual dose escalation was an important component of the published research protocols used to improve tolerability.

This section summarises published findings on investigational and clinical Semaglutide research and is not intended as guidance for use of this product.

Published dosing schedules used in Semaglutide research

Published Semaglutide studies generally employed once-weekly administration with gradual dose escalation, allowing investigators to evaluate both efficacy and gastrointestinal tolerability over extended treatment periods.

Across the major obesity and diabetes programmes, escalation protocols were used before reaching maintenance doses, with studies continuing for up to 68 weeks in obesity research. The published literature therefore reflects structured clinical trial design rather than a single universal dosing schedule.

These schedules summarise published clinical research design and are not instructions for use of this product.

Semaglutide vs Tirzepatide vs Retatrutide

Semaglutide

• GLP-1 receptor agonist
• single receptor mechanism
• largest clinical evidence base
• reference compound for GLP-1 research

Τιρζεπατίδη

• GLP-1 + GIP dual agonist
• broader incretin signalling
• frequently compared directly with Semaglutide

Ρετατρουτίδη

• GLP-1 + GIP + glucagon triple agonist
• broadest receptor profile
• represents the newest generation of multi-receptor metabolic peptides

For researchers investigating incretin biology, Semaglutide provides the foundation from which dual- and triple-agonist compounds can be evaluated.

Χαρακτηριστικά προϊόντος

Εφαρμογή: εργαστηριακή και αναλυτική έρευνα
Χρήση περιορισμού: όχι για ανθρώπινη κατανάλωση· όχι για ιατρική, κτηνιατρική ή καλλυντική χρήση
Παράγεται σε εγκαταστάσεις που συμμορφώνονται με τις ΟGMP υπό αυστηρά πρωτόκολλα ΠΚ.
Κάθε παρτίδα ελέγχεται προσεκτικά στο εργαστήριο μετά την παραγωγή (μπορείτε να βρείτε το Πιστοποιητικό Ανάλυσης κάτω από τις εικόνες του προϊόντος).
Κατάψυξη-αποξήρανση (λυσόφιλη) για μέγιστη σταθερότητα και παρατεταμένη διάρκεια ζωής.
Σφραγισμένα σε αποστειρωμένες φιάλες, έτοιμα για ανασύσταση.
Purity: ≥99% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Μοριακός τύπος: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight: 4113.64
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Αποθήκευση: τα αφυδατωμένα σε ξηρή ψύξη, σφραγισμένα φιαλίδια φυλάσσονται καλύτερα συντήρηση στους 2–8°C, η οποία είναι η μέθοδος αποθήκευσης που επιβεβαιώθηκε από τον συνεργάτη παραγωγής μας και είναι κατάλληλη για έως και 24 μήνες. Η ψύξη προτιμάται επειδή ελαχιστοποιεί τους περιττούς κύκλους ψύξης-απόψυξης κατά τον συνήθη χειρισμό. Εάν απαιτείται σημαντικά μακροχρόνια αποθήκευση, τα σφραγισμένα λυοφιλοποιημένα φιαλίδια μπορούν επίσης να διατηρηθούν κατεψυγμένα. Μόλις ανασυσταθεί, αποθηκεύετε πάντα σε 2–8°C και μην καταψύχετε.

Ανα

Semaglutide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with Βακτηριοστατικό νερό πριν τη χρήση. Τα πεπτίδια της κλάσης GLP-1 μερικές φορές διαλύονται αργά και απαιτούν πολύ ήπια ανασύσταση για να αποφευχθεί ο αφρός ή να παραμείνει ελαφρώς θολό.

Για την επιλογή άλλων διαλυτών, σχεδιασμό συγκεντρώσεων και οδηγίες αποθήκευσης, δείτε το πλήρες Οδηγός Ανασύστασης Πεπτιδίων και Υπολογιστής Απεικόνισης.

Βασικές δημοσιευμένες μελέτες

• Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021.
• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
• Aroda VR. A Review of the SUSTAIN Clinical Trial Programme. Diabetes, Obesity and Metabolism. 2019.

Συχνές Ερωτήσεις

What is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the activity of the naturally occurring incretin hormone glucagon-like peptide-1. It has become one of the most extensively studied metabolic peptides and serves as the reference compound for modern GLP-1 research. Published studies have investigated Semaglutide in relation to appetite regulation, glucose homeostasis, body-weight outcomes and broader cardiometabolic signalling.

How does Semaglutide work?

Semaglutide selectively activates the GLP-1 receptor, a pathway involved in regulating insulin secretion, glucagon release, gastric emptying and appetite signalling. Unlike newer dual- and triple-receptor agonists, it acts only on GLP-1 receptors, making it an important reference molecule for researchers comparing different incretin-based therapeutic strategies.

How is Semaglutide different from Tirzepatide?

Semaglutide activates only the GLP-1 receptor, whereas Tirzepatide is a dual GLP-1/GIP agonist. Both compounds belong to the incretin class, but Tirzepatide expands the mechanism beyond GLP-1 signalling. As a result, Semaglutide is often used as the benchmark against which dual agonists are evaluated in metabolic research.

How is Semaglutide different from Retatrutide?

Retatrutide is a triple agonist that targets GLP-1, GIP and glucagon receptors, giving it the broadest receptor profile currently under investigation among incretin peptides. Semaglutide, by contrast, focuses exclusively on GLP-1 receptor activation. This makes Semaglutide the foundational reference molecule for GLP-1 biology, while Retatrutide represents the next generation of multi-receptor metabolic research.

Why is Semaglutide still important when newer peptides exist?

Although newer dual- and triple-agonist peptides have generated considerable interest, Semaglutide remains one of the most important compounds in metabolic research because it has the largest and most mature body of published clinical evidence. Many studies evaluating Tirzepatide, Retatrutide and other investigational peptides continue to use Semaglutide as the primary comparator, making it central to understanding how newer incretin therapies differ from established GLP-1 receptor agonism.

What research areas commonly investigate Semaglutide?

Published studies have investigated Semaglutide across a broad range of metabolic research areas, including obesity, body-weight regulation, appetite signalling, glucose metabolism, type 2 diabetes, cardiovascular outcomes, fatty liver disease and long-term incretin biology. Its extensive evidence base makes it one of the most frequently referenced peptides in modern metabolic research.

How is Semaglutide supplied?

This product is supplied as 10 mg of lyophilised Semaglutide in a sterile research vial. Each batch is accompanied by a Certificate of Analysis (COA), and independent third-party analytical verification is available for selected batches. The product is intended exclusively for laboratory and analytical research.

Αυτό το προϊόν προορίζεται για ανθρώπινη χρήση;

No. Semaglutide supplied by LIFE Peptide is provided strictly for research use only. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published clinical studies on this page is included solely to summarise the current scientific literature surrounding the Semaglutide molecule.

Σχετικό ερευνητικό πλαίσιο

Semaglutide belongs to the GLP-1 receptor agonist class within incretin-based metabolic research. For mechanistic comparison with dual and triple agonists, see our Οδηγός μεταβολικής έρευνας GLP-1.

Περιηγηθείτε σε όλες τις ενώσεις στο Μεταβολική έρευνα.

For pathway comparison:

• Dual agonists:  Tirzepatide (GLP-1/GIP)

• Triple agonists: Retatrutide (GLP-1/GIP/glucagon)

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
Αυτό το προϊόν πωλείται αποκλειστικά για ερευνητικούς σκοπούς. Δεν προορίζεται για τη διάγνωση, θεραπεία, ίαση ή πρόληψη οποιασδήποτε ασθένειας. Ο αγοραστής αναλαμβάνει πλήρως την ευθύνη για τον σωστό χειρισμό και τη χρήση.